NWBO News and Press, Northwest Biotherapeutics Inc. From 10/05/20

Northwest Biotherapeutics ([[NWBO]] +2.6%) announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked.Pipeline:Independent service firms managing the clinical trial will now arrange for the independent statisticians to have access to the unblinded raw ...

Northwest Biotherapeutics Announces Data Lock of Phase III Trial PR Newswire BETHESDA, Md., Oct. 5, 2020 BETHESDA, Md. , Oct. 5, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® perso...

Executed and closed on August 28, 2020, Northwest Biotherapeutics ( OTCQB:NWBO +5.4% )   acquired Flaskworks, a developer of breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax, for $4.3M. More news on: Northwest Biotherapeutics, Inc....

BETHESDA, Md. , Sept. 1, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has devel...

BETHESDA, Md. , Aug. 27, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing...

Northwest Biotherapeutics ( OTCQB:NWBO +2.0% ) has completed a non-dilutive debt financing for net proceeds of additional $5M, via a 21-month note for $5.5M at an 8% annualized interest rate, with no payments due for the first 7 months. More news on: Northwest Biotherapeutics...

BETHESDA, Md. , Aug. 21, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a non-dilutive debt financing for net pr...

BETHESDA, Md. , Aug. 19, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company's ...

Northwest Biotherapeutics ( OTCQB:NWBO -2.9% ) has completed a financing of ~$8M, including ~$7M from offering at $0.32/share of new shares of ~21.8M shares with warrants averaging 21%, exercisable at $0.34 for ~5.3M shares, with an exercise period ranging from 18 to 30 months, and ...

Northwest Biotherapeutics ( OTCQB:NWBO ) : Q2 GAAP EPS of -$0.08. More news on: Northwest Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...